Evaluation of Possible Risk Factors of Lamivudine Resistance in Chronic Hepatitis B patients: A Retrospective Study in Iran

Nasser Daryani; Maryam Motamedi; Atoosa Miri; Parisa Poorsamimi; Sepideh Bidgoli

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue Accepted Manuscripts All Issues In Press Articles Search

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Evaluation of Possible Risk Factors of Lamivudine Resistance in Chronic Hepatitis B patients: A Retrospective Study in Iran

Author(s):

Nasser Daryani,

Maryam Motamedi,

Atoosa Miri,

Parisa Poorsamimi,

Sepideh Bidgoli^1,*

1Department of Toxicology & Pharmacology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran

Hepatitis Monthly:Vol. 9, issue 3; 171-179

Published online:Sep 30, 2009

Article type:Research Article

Received:Jan 12, 2009

Accepted:Apr 30, 2009

How to Cite:Daryani N, Motamedi M, Miri A, Poorsamimi P, Bidgoli S. Evaluation of Possible Risk Factors of Lamivudine Resistance in Chronic Hepatitis B patients: A Retrospective Study in Iran.Hepat Mon.2009;9(3):171-179.

Abstract

Background and Aims: Clinical resistance to lamivudine (LAM) can lead to exacerbation and high-level cross-resistance to all L-nucleotides in chronic hepatitis B patients, but the underlying reasons for this remain unclear. This study aimed to compare the clinicopathological features of LAM-resistant and LAM-responsive patients and tried to detect the tissue levels of Glutathione S-transferas pi (GSTpi) in the naive biopsies of both groups to find possible risk factors of LAM resistance.

Methods: Patients with naive biopsies and successful LAM therapy for one year were included as controls (n = 25), and patients who interrupted their LAM regimen during clinical relapse (n = 16) were considered cases. Clinicopathological characteristics of patients and GSTpi levels were compared between the two groups by an immunohistochemical analysis.

Results: Although no significant difference was detected between tissue levels of GSTpi in cases and controls, statistical tests showed a significant role of prior interferon-alpha (IFN-a) (P = 0.024, odds ratio [OR] = 5.25) therapy and higher HAI scores (P = 0.05, OR = 4.08) of naive biopsy samples and emphasized their roles as two relative risk factors for LAM resistance. Half of the cases showed higher HAI scores (> 6) whereas only 19% of controls showed the same pattern. A higher rate of LAM withdrawal was detected in patients with a history of IFN therapy (P = 0.024), and a history of IFN therapy was considered to be a possible risk factor of LAM withdrawal (OR = 5.21). Higher HAI scores were also detected in patients with a history of INF therapy (P = 0.041, OR = 4.8), and a history of INF therapy was considered to be a possible risk factor of tyrosine-methionine-aspartate-aspartate (YMDD) mutation (OR = 3.83).

Conclusions: This study has introduced two possible new predictive markers of LAM resistance in chronic hepatitis patients, which should be confirmed in future studies with larger groups to optimize the best pharmacotherapy regimens in chronic hepatitis B patients and may help physicians reduce the risk of adverse drug reactions.

Keywords

Chronic Hepatitis B

Lamivudine

Glutathione S-transferas pi

Cross Resistance

Interferon-Alpha

Fulltext

Full text is available in PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 4 days ago
Scopus by Title: 2
Last Update: 4 days ago
Scopus by Title (Ref): 2
Last Update: 4 days ago
CrossRef: 0
Last Update: 4 days ago

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Nasser Daryani:[PubMed][Scholar]
Maryam Motamedi:[PubMed][Scholar]
Atoosa Miri:[PubMed][Scholar]
Parisa Poorsamimi:[PubMed][Scholar]
Sepideh Bidgoli:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

Evaluation of Possible Risk Factors of Lamivudine Resistance in Chronic Hepatitis B patients: A Retrospective Study in Iran

Abstract

Fulltext

Last Update: 4 days ago

Last Update: 4 days ago

Last Update: 4 days ago

Last Update: 4 days ago